Cloud DX and Medtronic Sign First Contract with Ontario Hospital

Cloud DX and Medtronic Sign First Contract with Ontario Hospital

Healthcare collaboration's first Remote Patient Monitoring deployment with St. Mary's General Hospital for Virtual COPD (Chronic Obstructive Pulmonary Disease) program

News in Summary

First joint deployment for Cloud DX and Medtronic since their announcement of a strategic collaboration
Hospital contract with St. Mary's General hospital in Kitchener, Ontario
Initial deployment to support Pulmonary Rehab, with growth into other practices in the hospital

Cloud DX (TSXV:CDX) (OTC:CDXFF), a leading Virtual Care platform, and its partner Medtronic Canada ULC, a subsidiary of global healthcare leader Medtronic plc (NYSE:MDT), signed their first joint Remote Patient Monitoring contract. The contract will support Virtual Care delivery at St. Mary's General Hospital, in Kitchener, Ontario, and will commence with an initial deployment for the hospital's COPD Activation Program. The program will support pulmonary COPD rehab patients with online education and rehab therapy sessions twice a week over a four-week period. The contract comes as Cloud DX gains recognition as a leader in providing pulmonary therapy support and reports multiple high satisfaction ratings

"We are pleased to announce this traction in our partnership with Cloud DX, the first of many contracts together. In our commitment to developing the virtual healthcare pathway, we are thrilled to work with Cloud DX and innovative hospitals, such as St. Mary's General Hospital," said Jessica Rudd, Director New Partnerships and Solutions at Medtronic Canada. "Virtual Care is a key component in the future of healthcare; it enhances many aspects of healthcare delivery from post-surgical support to at-home pulmonary rehab. It can bring patients and care teams closer together, improves patient outcomes, and helps to address our overloaded healthcare system. We look forward to supporting St. Mary's in delivering these benefits and growing our relationship together."

"Innovation is a priority at St. Mary's Hospital. Embracing new ways to deliver healthcare is important for our patients, staff, as well as the broader community. Innovations like Virtual Care delivery improves patient outcomes, and lowers hospitalization rates and re-admissions," added Sarah Farwell, Director, Strategy, Innovation and Communications at St. Mary's General Hospital. "As a direct result, it can alleviate burden on our hospital system, as well as help patients and their care teams better manage their condition and keep them well in the community. We anticipate these types of outcomes for patients of the pulmonary COPD rehab program, by partnering with our vendor of choice, Cloud DX and Medtronic. Patients love the easy-to-use technology. Our clinical team appreciates the thoughtfully developed clinician dashboard which eases workload and facilitates patient compliance. We're excited to be making strides in our goals to innovate healthcare, with healthtech leaders like Cloud DX and Medtronic."

"As a Kitchener based MedTech company, it is exciting to support a local hospital. With St. Mary's we will begin with the COPD Activation Program. This innovative program will offer online education and therapy sessions all via our Connected Health™ platform. It is clear this partnership between two renowned providers of healthcare services is an indication of things yet to come - especially when looking into how much more Virtual Care we can expect moving forward," said Robert Kaul, CEO and Founder of Cloud DX.

About Medtronic Canada ULC

Bold thinking. Bolder actions. We are Medtronic. Proud to serve Canadian healthcare for over 50 years, Medtronic Canada ULC is headquartered in Brampton, Ontario, with regional offices in Montreal and Vancouver, and is a subsidiary of Medtronic plc. We are the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 90,000+ passionate people. Our technologies and therapies address 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. In everything we do, we are engineering the extraordinary. Learn more at www.medtronic.ca.

About Cloud DX

Accelerating virtual healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers." In 2021, Cloud DX became an exclusive partner to Medtronic Canada.

Cloud DX Investor Sitehttps://ir.clouddx.com/overview/default.aspx

About St. Mary's General Hospital:

Located in the heart of Kitchener, Ontario, St. Mary's known provincially and nationally as a leader in innovation, patient safety, and patient satisfaction. It is the second-largest acute care hospital in the St. Joseph's Health System and a Regional Cardiac Care and Thoracic Centre. St. Mary's proudly serves the residents of Waterloo, Wellington County, and extends its reach to Dufferin, Grey-Bruce and beyond.

St. Mary's is a Top 100 Forbes Canada's Top Employers with a dedicated, talented and passionate team of nearly 2,000 staff, physicians and volunteers. This team provides high-quality, compassionate care to hundreds of thousands of patients and families every year in our core areas of clinical focus:

  • Cardiac Care (Regional Cardiac Centre)
  • Respiratory Care (Level 1 Thoracic Surgery Centre)
  • Outpatient (Day) Surgery
  • General Medicine
  • 24/7 Emergency Care

Learn more about Our Mission, Values & History and the future of care at St. Mary's.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Social Links

Twitter https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/

For media inquiries please contact:

Janine Scott Melicent Lavers
Marketing Lead Medtronic Canada Public Relations
888-543-0944 +1-905-460-3653
janine.scott@CloudDX.com

For investor inquiries please contact:

Jay Bedard Ryan Weispfenning
Cloud DX Investor Relations Medtronic plc Investor Relations
647-881-8418 +1-763-505-4626
jay.bedard@CloudDX.com

SOURCE: Cloud DX



View source version on accesswire.com:
https://www.accesswire.com/689912/Cloud-DX-and-Medtronic-Sign-First-Contract-with-Ontario-Hospital

News Provided by ACCESSWIRE via QuoteMedia

CDX:CA
The Conversation (0)
Cloud DX partners with Sheridan College on Medical Metaverse Research and Development

Cloud DX partners with Sheridan College on Medical Metaverse Research and Development

Developing the Clinic of the Future, Cloud DX work to be supported by Sheridan College through federal grant

News in Summary

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Signs Contract with Paramedical Service Provider for Remote Patient Monitoring

Cloud DX Signs Contract with Paramedical Service Provider for Remote Patient Monitoring

Cloud DX chosen as Virtual Care Platform for the Ontario Paramedical Service provider, replacing existing hardware and services

Cloud DX (TSXV:CDX)(OTCQX:CDXFF) is pleased to announce a new 24-month contract with an Ontario Paramedic Service Provider enabling the client to provide Remote Patient Monitoring (RPM) across its serviceable area. Cloud DX will provide its award-winning Connected Health™ platform and support the client as it transitions from its previous remote care tools to Cloud DX's Virtual Care Platform. The client showcases how beneficial ‘Remote Care Monitoring' is for Paramedical Service providers, enabling providers to establish deeper community roots and maintain funding levels, while community members benefit from greater access to much-needed care. The client has purchased 223 Connected Health™ kits totalling ~$145,000 CAD with additional recurring fees for subscription software services. Funding for the program comes from the $82.5M Community Paramedicine for Long-Term Care program announced by the Ontario government on October 22, 2021

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Signs Two Contracts with US Primary Care Clinics

Cloud DX Signs Two Contracts with US Primary Care Clinics

Continued growth in US RPM as partner Maxwell Telecare signs two additional clinics in Illinois

News in Summary

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Signs New Palliative Contract with Ontario Healthcare Team

Cloud DX Signs New Palliative Contract with Ontario Healthcare Team

Cloud DX Signs New Palliative Contract with Ontario Healthcare Team

Healthcare team to use Connected Health™ kits to provide dignity in care for up to 85 patients

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Announces Closing of Private Placement

Cloud DX Announces Closing of Private Placement

Cloud DX (TSXV:CDX)(OTCQB:CDXFF), a leading North American provider of virtual care and Remote Patient Monitoring (RPM) solutions, is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of 260 units (the "Units") of the Corporation at a price of $1,000 per Unit, for gross proceeds of $260,000 (the "Offering"). Each Unit is comprised of (i) a C$1,000 principal amount unsecured convertible debenture (each, a "Debenture") and (ii) 1,430 common share purchase warrants of the Corporation (each, a "Warrant"). The Debentures will mature on January 27, 2025 (the "Maturity Date") and shall bear interest at a simple rate of 10% per annum. The principal amount of the Debentures may be converted at the election of the holder thereof into common shares in the capital of the Company ("Common Shares") at a conversion price of C$0.35 per Common Share (the "Conversion Price") at any time prior to the Maturity Date. Each Warrant entitles the holder thereof to acquire one common share of the Corporation (each, a "Common Share") at a price of C$0.50 per Common Share at any time prior to 4:30 p.m. (Toronto Time) on January 27, 2024

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Syntheia Rings the Opening Bell on the Canadian Securities Exchange

Syntheia Rings the Opening Bell on the Canadian Securities Exchange

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, a Canadian leader in conversational AI, is pleased to announce that the Company's leadership team rang the bell to open the market in collaboration with the Canadian Securities Exchange to celebrate its successful listing under the symbol "SYAI".

" We look forward to great success through our partnership with the CSE as we commercially launch our conversational AI to the market. On behalf of the Company, I would like to thank everyone who has made this milestone happen, " commented Tony Di Benedetto, Chief Executive Officer at Syntheia.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Provaris Energy

Notice of Initial Substantial Holder - Regal Funds Management Pty Ltd

Provaris Energy Ltd (ASX.PV1, Provaris, the Company) is pleased to present the notice of initial substantial holder.


Keep reading...Show less
Syntheia Set to Enhance Customer Communication with Its AI-Powered Virtual Assistant

Syntheia Set to Enhance Customer Communication with Its AI-Powered Virtual Assistant

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, a Canadian leader in conversational AI, announces that its innovative SaaS platform, designed to transform how businesses manage inbound telephone calls is set to launch in January of 2025. Leveraging advanced Natural Language Processing (NLP), Syntheia's virtual assistants enhance communication and efficiency targeting small and medium businesses in this large global marketplace.

" Our mission is to eliminate as many inefficiencies as we can with managing inbound calls that small to medium-sized businesses face utilizing the power of AI" said Tony Di Benedetto, CEO of Syntheia. "With AI-driven virtual assistants, we provide these businesses with tools to improve customer satisfaction while reducing operational costs. We are gearing up now for commercial launch in January of 2025, less than 8 weeks away."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Canadian Securities Exchange Reports October 2024 Performance Figures

Canadian Securities Exchange Reports October 2024 Performance Figures

The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for October 2024.

October 2024 Operating Statistics

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update

Sona Nanotech to Showcase Its THT Cancer Therapy at NCL 20th Anniversary Symposium and Provides Corporate Update

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that its Chief Scientific Officer, Dr. Len Pagliaro, has been invited to showcase Sona's developing Targeted Hyperthermia Therapy ("THT") cancer treatment today at the Nanotechnology Characterization Laboratory ("NCL"). Sona will be one of six commercial and academic collaborators to present its research at the NCL's 20th anniversary "Advancing Medical Applications of Cancer Nanotechnology" symposium. Sona's subsidiary was previously selected for the NCL Assay Cascade Program, the premier program in the World for bringing nanomaterials through critical preclinical stages and facilitating regulatory review, in which Sona's materials were assessed for biocompatibility. The NCL was established by the National Cancer Institute ("NCI") to accelerate the progress of nanomedicine by providing preclinical characterization and safety testing of nanoparticles. The NCL is a collaborative effort between NCI, the U.S. Food and Drug Administration ("FDA"), and the National Institute of Standards and Technology.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

Quarterly Activities Report and Appendix 4C - 30 Sept 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following Quarterly Activities Report and Appendix 4C for the quarter ending 30th September 2024 together with an Operational Update.

Keep reading...Show less

Latest Press Releases

Related News

×